Clinicians Should Consider Patient Concerns Amid Rise in Early-Onset Cancers

Commentary
Video

Clinicians should not dismiss the concerns of younger patients who suspect they may have breast cancer, especially amid an increase in early-onset disease according to Monique Gary, DO, MSc, FACS.

Although breast cancer has been historically recognized as a disease associated with aging, it is crucial to encourage younger populations of patients to stay vigilant of potential symptoms due to earl-onset incidence increasing over time, Monique Gary, DO, MSc, FACS, said during a conversation with CancerNetwork®.

In an interview concerning the findings from a study published in JAMA Network Open that highlighted a rise in early-onset breast cancer from 2010 to 2019, Gary, a breast surgeon and medical director at Grand View Health, emphasized the importance of listening to patient concerns and taking them seriously, as it could be a matter of life or death.

Transcript:

We should pay attention to the patient, and not just the patterns. Too often, young people are dismissed because they don’t fit the typical mold of what cancer looks like. We have historically been taught that cancer is largely a disease of aging. And while there are juvenile and pediatric cancers, historically, breast cancer hasn’t been one of them, [as well as] uterine cancer and colon cancer. Because we’re seeing younger and younger people develop these cancers, it means that we need to pay attention to those symptoms, [and] it means that we need to teach young people to pay attention to their bodies and not just power through without understanding the changes because they’re too young for screening. It’s not like you just have to wait for a colonoscopy. By the time you wait for that colonoscopy, you may have advanced disease or you could be dead.

You have to learn to listen to your body. We have to teach that we have to learn to listen to and believe our patients. Those are really great takeaways from this.

Reference

Koh B, Hao Tan DJ, Ng HN, et al. Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019. JAMA Netw Open. 2023;6(8):e2328171. doi:10.1001/jamanetworkopen.2023.28171

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.